EC Paediatrics

Research Article Volume 12 Issue 4 - 2023

Pulmonary Aspergillosis in Pediatric Patient

Coral-García Miguel Ángel1, Serrano-Guevara Christian Mauricio2, León-López Magdalena2, López-Santos Héctor Alfonso3, Barbosa-Contreras Meylin3, Maldonado-Castañeda Sandra2, Rubio-Nava Karla María1, Guevara-Navarrete César Martín3, Silva-Campos Irlanda Mariel3 and Yaneth Martínez Tovilla3*

1International Laboratory EPIGEN- CONCYTEP- BUAP, Mexico
1General Hospital “Dr. Eduardo Vázquez Navarro”, México
2Facultad de Medicina, Benémerita Universidad Autónoma de Puebla, México

*Corresponding Author: Yaneth Martínez Tovilla, Facultad de Medicina, Benémerita Universidad Autónoma de Puebla, Puebla, Mexico.
Received: February 21, 2023; Published: March 17, 2023

Introduction: Aspergillus is a branched septate filamentous fungus that can induce lethal and invasive infections in patients suffering from autoimmune or inflammatory diseases, as well as patients undergoing organ transplantation and/or treatment for malignant neoplasms [5]. Since aspergillosis is not a reportable infection in many countries, it is difficult to have an accurate estimate of the number of cases worldwide. Even so, most cases of this disease are sporadic and occasionally in hospitalized patients, with a reported mortality of 30% to 85% [6].

Voriconazole is the recommended drug in invasive aspergillosis, which is an azole agent that inhibits cytochrome P450 (CYP 450)-dependent demethylation of 14α-lanosterol in the synthesis of ergosterol in the fungal cell membrane [7].

The importance of this work lies in the need to recognize in early stages this pathology, often diagnosed in autopsies. Therefore, we offer a clinical perspective on the comprehensive approach to invasive pulmonary aspergillosis in a pediatric patient.

Case: 15-year-old male with no relevant history. He was admitted to the General Hospital of Puebla "Dr. Eduardo Vazquez Navarro" after suffering trauma to the frontal bone of the skull (kicked by an equine). After his recovery, he presented fever despite administration of ceftriaxone and vancomycin, for which reason meropenem was added and a bronchial aspirate culture was obtained with a report of Aspergillus fumigatus; a positive determination of galactomannan in bronchial aspirate; a chest CT scan with ground glass image in the right upper lobe, consolidation at the level of segments 6 - 10 right and right basal laminar atelectasis. Overall, a diagnosis of pulmonary aspergillosis was made and treatment with voriconazole was started. Once stable, the patient was discharged with the following drugs: voriconazole, levetiracetam, carbamazepine, captopril, omeprazole, beclomethasone and prednisone, as well as follow-up and outpatient appointment by the pediatrics, neurology, pneumology and cardiology specialties.

Pulmonary aspergillosis is a disease that induces high mortality due to its late diagnosis. Early diagnosis and efficient targeted therapy had a positive impact on the prognosis of this patient. Aspergillus infections can be catastrophic in different situations. Clinical suspicion and efficient use of different healthcare resources (e.g. laboratory and imaging studies) can improve the prognosis of these patients.

Keywords: Aspergillosis; Pulmonary; Pediatric; Report Case

  1. Wiener Charles., et al. “Harrison’s Principles of Internal Medicine Self-Assessment and Board Review, 20th Edition”. McGraw Hill Professional (2021).
  2. Shariati Aref., et al. “Aspergillosis of Central Nervous System in Patients with Leukemia and Stem Cell Transplantation: A Systematic Review of Case Reports”. Annals of Clinical Microbiology and Antimicrobials1 (2021).
  3. Fortu N., et al. “Aspergilosis. Formas Clí nicas Y Tratamiento”. Enfermedades Infecciosas Y Microbiologí a Clí nica4 (2012): 201-208.
  4. Chabi ML., et al. “Pulmonary Aspergillosis”. Diagnostic and Interventional Imaging5 (2015): 435-442.
  5. Kousha M., et al. “Pulmonary Aspergillosis: A Clinical Review”. European Respiratory Review121 (2011): 156-174.
  6. A Vazquez Jose., et al. “The Changing Epidemiology of Invasive Aspergillosis in the Non-Traditional Host: Risk Factors and Outcomes”. Pulmonary and Critical Care Medicine3 (2016).
  7. Sanati H., et al. “A New Triazole, Voriconazole (UK-109,496), Blocks Sterol Biosynthesis in Candida Albicans and Candida Krusei”. Antimicrobial Agents and Chemotherapy11 (1997): 2492-2496.
  8. We RY Nathalie. “Bioaerosols from composting facilities a review”. Frontiers in Cellular and Infection Microbiology 4 (2014).
  9. Panse Prasad., et al. “The Many Faces of Pulmonary Aspergillosis: Imaging Findings with Pathologic Correlation”. Radiology of Infectious Diseases4 (2016): 192-200.
  10. Panse Prasad., et al. “The Many Faces of Pulmonary Aspergillosis: Imaging Findings with Pathologic Correlation”. Radiology of Infectious Diseases4 (2016): 192-200.
  11. Simsek Turgay., et al. “Response to Trauma and Metabolic Changes: Posttraumatic Metabolism”. Turkish Journal of Surgery3 (2014): 153-159.
  12. Arastehfar A., et al. “Aspergillus Fumigatus and Aspergillosis: From Basics to Clinics”. Studies in Mycology 100 (2021): 100115.
  13. Beigelman-Aubry Catherine and Sabine Schmidt. “Pulmonary Infections: Imaging with CT”. Multidetector-Row CT of the Thorax (2016): 131-161.
  14. Rosowski Emily E., et al. “Efficacy of Voriconazole against Aspergillus Fumigatus Infection Depends on Host Immune Function”. Antimicrobial Agents and Chemotherapy2 (2019).
  15. “Voriconazol | Asociacio n Espan ola de Pediatrí” (2021).
  16. Mori Masaaki., et al. “Pharmacokinetics and Safety of Voriconazole Intravenous-To-Oral Switch Regimens in Immunocompromised Japanese Pediatric Patients”. Antimicrobial Agents and Chemotherapy2 (2015): 1004-1013.
  17. “Fungal Culture”. Aspergillus and Aspergillosis (2022).
  18. Patterson Thomas., et al. Health Science Center at San Antonio and South Texas Veterans Health Care System (2021).
  19. “Ficha – Coloracio n de Grocott”. Sociedad de Citologí a (2020).
  20. D’Haese Jorien., et al. “Detection of Galactomannan in Bronchoalveolar Lavage Fluid Samples of Patients at Risk for Invasive Pulmonary Aspergillosis: Analytical and Clinical Validity”. Journal of Clinical Microbiology4 (2012): 1258-1263.
  21. Mohammadi Shilan., et al. “Bronchoalveolar Galactomannan in Invasive Pulmonary Aspergillosis: A Prospective Study in Pediatric Patients”. Respiratory Infections1 (2015).
  22. De Heer Koen., et al. “Galactomannan Detection in Broncho-Alveolar Lavage Fluid for Invasive Aspergillosis in Immunocompromised Patients”. Cochrane Database of Systematic Reviews 4 (2019).
  23. Wu Jing., et al. “Characteristics of the Computed Tomography Imaging Findings in 72 Patients with Airway-Invasive Pulmonary Aspergillosis”. Medical Science Monitor 27 (2021).

Miguel Ángel Coral-García., et al. Pulmonary Aspergillosis in Pediatric Patient. EC Paediatrics 12.4 (2023):25-31.